Perhydrothiazepine derivatives, their preparation and their therapeutic use

Claim 1

Compounds of formula (I): wherein: R represents a C 1 -C 10 alkyl group, a C 3 -C 8 cycloalkyl group, a carbocyclic aryl group having from 6 to 14 ring carbon atoms, a partially hydrogenated carbocyclic aryl group having from 6 to 14 ring carbon atoms or a heterocyclic group having from 5 to 14 ring atoms, of which from 1 to 5 are nitrogen, sulphur or oxygen hetero-atoms, said groups represented by R 1 being unsubstituted or having at least one substituent selected from the group consisting of: (a) oxo groups, C 1 -C 6 alkyl groups, C 6 -C 10 carbocyclic aryl groups, aralkyl groups wherein the alkyl part is C 1 -C 6 alkyl and the aryl part is C 6 -C 10 carbocyclic aryl, hydroxy groups, C 1 -C 6 alkoxy groups, alkoxyalkoxy groups where each alkoxy part is C 1 -C 6 , aralkyloxy groups, wherein the alkoxy part is C 1 -C 6 alkoxy and the aryl part is C 6 -C 10 carbocyclic aryl, aryloxy groups wherein the aryl part is C 6 -C 10 carbocyclic aryl, halogen atoms, nitro groups, cyano groups, carboxy groups, alkoxycarbonyl groups wherein the alkoxy part is C 1 -C 6 alkoxy, amino groups, C 1 -C 6 alkylamino groups, dialkylamino groups wherein each alkyl part is C 1 -C 6 alkyl, aliphatic or carbocyclic aromatic carboxylic acylamino groups, carbamoyl groups, alkylcarbamoyl groups where the alkyl part is C 1 -C 6 alkyl, dialkylcarbamoyl groups where each alkyl part is C 1 -C 6 alkyl, C 1 -C 6 alkylthio groups, C 6 -C 10 carbocyclic arylthio groups, C 1 -C 6 alkylsulphonyl groups and C 6 -C 10 carbocyclic arylsulphonyl groups wherein the aryl part is unsubstituted or has from 1 to 3 C 1 -C 6 alkyl substituents; R 2 , R 3 , R 4 and R 5 are the same or different and each represents a hydrogen atom, a C 1 -C 10 alkyl group, a C 3 -C 8 cycloalkyl group, an aralkyl group wherein the alkyl part is C 1 -C 6 alkyl and the aryl part is C 6 -C 10 carbocyclic aryl, a C 6 -C 14 carbocyclic aryl group, a C 1 -C 6 alkyl group having a heterocyclic substituent wherein the heterocyclic part has from 5 to 10 ring atoms of which from 1 to 5 are nitrogen, sulphur or oxygen hetero-atoms, or a heterocyclic group having from 5 to 14 ring atoms of which from 1 to 5 are nitrogen, sulphur or oxygen hetero-atoms, provided that R 2 , R 3 , R 4 and R 5 do not all represent hydrogen atoms, said groups represented by R 2 , R 3 , R 4 and R 5 being unsubstituted or having at least one substituent selected from the group consisting of the substituents defined in (a) above, or R 2 and R 3 , R 4 and R 5 or R 2 and R 4 together form a saturated carbocyclic or heterocyclic ring having from 3 to 6 ring atoms, of which, in said heterocyclic ring, from 1 to 3 are nitrogen, sulphur or oxygen hetero-atoms, or R 2 and R 3 , R 4 and R or R 2 and R 4 together form a saturated carbocyclic ring having 5 or 6 ring atoms, which ring is fused with a C 6 - C 10 carbocyclic aryl system; A represents a direct carbon-carbon bond, a methylene group, an ethylene group, an oxymethyl group or a thiomethyl group; B represents a C 1 -C 4 alkylene or alkylidene group or a C 3 -C 6 cycloalkylene or cycloalkylidene group n is 0, 1 or 2; and pharmaceutically acceptable salts and esters thereof.